From a partnering event being held at MassBio's HQ in Kendall Square, Ken Takeshita describes Daiichi's targets under development beyond...

Josh Cohen and Justin Klee explain why they chose this program, and what the potential timeline looks like for a phase 3 trial. Plus, an...

CEO William Chou describes the scientific rationale for elevating progranulin, what the company has seen in the first three patients...

A developer of ADCs today, CEO Robin Carr describes how the company’s N-myristoyltransferase (NMT) payload approach sets them apart.

Denise Scots-Knight describes what Mereo and its partner Ultragenyx have seen in setrusumab data over time, and her description of the...

Thierry Bernard describes the scientific advances underlying QIAGEN's four business pillars: sample technologies, diagnostic solutions,...

John Quisel describes how bitopertin aims to reduce PPIX, a photosensitiser that makes it painful for patients when exposed to light....

Joanna Stanicka describes how Axonis is developing a small molecule that is KCC2-potentiating, with the idea to restore the role that...

Angela Ruban describes how NeuroHagana is developing a treatment to lower blood glutamate levels that she believes would ideally be...

Paul Bradshaw explains how Inteligex's "ReStaRT Cells" are designed with a regional identity, and the rationale for engineering them to...

Mike Kelly explains the scientific rational for this peptide-based treatment, highlights its preclinical and phase 1 profile, and...

Laura Sepp-Lorenzino shares details of this news and offers her opinion of the significance of it, and provides an overview of Intellia's...

Brian Culley describes the need for an spinal cord injury focused investor conference and how the SCI Investor Symposium has grown over...

Paul Bolno highlights biomarker and safety data in Huntington's, the potential regulatory path ahead, and what to watch throughout the rest

She describes how patients might benefit from UroGen's gel based technology that keeps chemotherapy locally in the bladder vs having...

David Domzalski discusses how Vyne is using this target that is traditionally thought of in oncology.

Tom Miller describes the rationale for the raise and what it will allow Iambic to do, how he believes the company's AI approach is unique

Yvonne Greenstreet shares her thoughts on key points of today's top-line, but as monotherapy and in combination, the potential market, and w

Michael McElhaugh describes data presented at EASL for the RNAi therapeutics imdusiran, explains the rationale for the PD-L1, and more.

Mike Ehlers describes how this $42M upfront and up to $1.8B in potential milestones deal is focused on neurological conditions, how RNA...